These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Natalizumab for multiple sclerosis? Drug Ther Bull; 2008 Sep; 46(9):69-72. PubMed ID: 18784381 [TBL] [Abstract][Full Text] [Related]
4. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA; Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550 [TBL] [Abstract][Full Text] [Related]
5. [Natalizumab (Tysabri) prescription practices of neurologists in southern France]. Rocher F; Cohen M; Lebrun C Rev Neurol (Paris); 2010 Apr; 166(4):412-8. PubMed ID: 19846185 [TBL] [Abstract][Full Text] [Related]
6. Natalizumab for relapsing-remitting multiple sclerosis. Horga A; Tintoré M Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250 [TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of natalizumab for formulary consideration. Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228 [TBL] [Abstract][Full Text] [Related]
8. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis. Rinaldi F; Perini P; Calabrese M; Rinaldi L; Gallo P Mult Scler; 2009 Nov; 15(11):1359-62. PubMed ID: 19812116 [TBL] [Abstract][Full Text] [Related]
9. Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy. Berger JR Mult Scler; 2008 Jun; 14(5):708-10. PubMed ID: 18566035 [TBL] [Abstract][Full Text] [Related]
10. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
11. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711 [TBL] [Abstract][Full Text] [Related]